In breast cancer, high-risk patients (triple-negative/HER2+/≥4 lymph nodes) screened with 18F-FDG PET/CT plus serum CTX achieve 96% sensitivity, ECT-positive lesions confirmed by 3.0T MRI/DWI reach 99% specificity (74). This evidence concerns the gene ERBB2 and breast carcinoma.